News | News By Subject | News by Disease News By Date | Search News

Staphylococcal infection News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
BIOCEO15: ContraFect (CFRXU) CEO Says Lysin, AB Anti-Infectives Are “Game-Changers” in 2015     2/10/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Pfizer Inc. (PFE), GlaxoSmithKline (GSK) and NovaDigm Therapeutics ' Vaccine for Staph More Lethal Than Skin Cancer Tested     9/17/2012
Inhibitex, Inc. (INHX) Reports Top-Line Results In Phase III Study Of Veronate(R) - Failed To Meet Its Primary Endpoint     4/3/2006
Nabi Biopharmaceuticals (NABI) Updates European Commercialization Strategy; Closes European Operations     12/20/2005
Nabi Biopharmaceuticals (NABI) Reports Favorable StaphVAX News And Completes $20 Million Florida Vaccine Plant     10/14/2005
Nabi Biopharmaceuticals (NABI) Announces Successful Results From StaphVAX(R) Consistency Lots Study     10/13/2005
Inhibitex, Inc. (INHX) Release: Data Safety Monitoring Board Unanimously Recommends Continuation Of Veronate Phase III Trial As Designed     9/6/2005
Nabi Biopharmaceuticals (NABI) Release: StaphVAX(R) Immunogenicity Study In Cardiac Patients Meets Primary Endpoints Of Safety And Immune Response     7/12/2005
Schering-Plough Corporation (SGP) Announces FDA Approval Of AVELOX(R) (moxifloxacin HCl) For Treatment Of Complicated Skin And Skin Structure Infections     6/30/2005
CUBICIN Meets Primary Endpoints In Ground-Breaking Staphylococcus Aureus Endocarditis/Bacteremia Study; Cubist Pharmaceuticals, Inc. (CBST) Plans To File sNDA For Expanded Label Before Year-End     6/28/2005
Inhibitex, Inc. (INHX) Reports Favorable Results From Aurexis Phase II Trial For The Treatment Of Staph Bloodstream Infections     5/9/2005
Vicuron Pharmaceuticals, Inc. (MICU) Granted Priority Review Of Dalbavancin NDA By FDA In Complicated Skin And Soft Tissue Infections     2/24/2005
Nabi Biopharmaceuticals' (NABI) StaphVAX(R) MAA Accepted For Review By The European Medicines Evaluation Agency     1/27/2005

News from Around the Web
New Research Raises Questions About Using Certain Antibiotics To Treat "Superbug" MRSA, Cedars-Sinai Medical Center Study     11/13/2015
Sunscreen Ingredient May Prevent Medical Implant Infections, University of Michigan Study     11/12/2015
Planes Can Harbor Deadly Germs For 7 Days, Auburn University Study     5/21/2014
Antibiotic-Resistant MRSA "Superbug" Found In U.S. Homes, Columbia University Medical Center Study     4/24/2014
Chemical Compounds in Trees Can Fight Deadly Staph Infections in Humans, University of Missouri Study     2/25/2011
Drug-Resistant Staph Infections Decline In Hospitals, University of Iowa Study     8/11/2010
Genes Key To Staph Disease Severity, Drug Resistance Found Hitchhiking Together, National Institute of Allergy And Infectious Diseases (NIAID), University of Tubingen, And University of Medicine and Dentistry of New Jersey Study     8/3/2009
New Technology Shows Promise Against Resistant Staph Infections, Albert Einstein College of Medicine Study     5/1/2009
Doubts Raised Over MRSA Screening,University of Geneva Study     3/12/2008
Immune System Protein Starves 'Staph' Bacteria, Could Lead To New Treatments     2/20/2008
New Approach May Render Disease-causing Staph Harmless     2/18/2008
Novel Approach Strips Staph Of Virulence     2/15/2008
Studies Highlight MRSA Evolution And Resilience     1/22/2008
Best Treatment Identified To Reduce Deadly Staph Infections, According To Expert     12/5/2007
Scientists Identify Factor Key to Severity of Community-Associated Methicillin-Resistant Staph Infections     11/12/2007

Press Releases
Aridis Pharma Presents Positive Phase IIa Safety And Efficacy Data Of Salvecin (AR-301) In Patients With Severe Pneumonia Caused By Staphylococcus Aureus During The 2017 ASM Microbe Congress     6/5/2017
Theravance Biopharma (TBPH) Release: New Data Highlighting In Vitro Potency Advantages For VIBATIV (Telavancin) Against Difficult-To-Treat MRSA And MSSA Pathogens Reported At ASM Microbe 2017     6/5/2017
Intralytix And BioPhage Therapeutics Partner To Develop Topical Bacteriophage Treatments Of Human Wounds Infected With S. Aureus     4/5/2017
XBiotech (XBIT) Reports Top-Line Results For 514G3 Antibody Therapy In Serious Staphylococcus Aureus Infections     4/4/2017
Debiopharm Release: Biopharma Announces Positive Phase 2 Clinical Trial With Debio 1450 In ABSSSI Patients     1/10/2017
BIO2016: AmpliPhi Bio (APHB)’s CEO To Discuss Novel Approaches To Fighting Drug-Resistant Pathogens In Panel At BIO International     5/31/2016
AmpliPhi Bio (APHB) Announces Start Of First Phage Therapy Trial In U.S. Under IND     5/24/2016
Theravance Biopharma (TBPH) Release: New Data Analyses From Phase 3 ATTAIN Trials Support VIBATIV (Telavancin) As A Treatment For Staphylococcus Aureus HABP/VABP, Including Cases Caused By MRSA     5/16/2016
AmpliPhi Bio (APHB) Reports First Quarter 2016 Financial Results And Provides Corporate Update     5/13/2016
ProMetic Life Sci (PFSCF.PK) Announces Successful Treatment Of A Plasminogen-Deficient Patient Under An Expanded Access (Compassionate Use) Protocol In The USA     5/3/2016
XBiotech Advances To Phase II Portion Of Clinical Study Of Novel True Human Therapeutic Antibody For Treating Serious Infections Due To Staphylococcus Aureus     3/28/2016
XBiotech Enrolls Final Patient In Phase I Portion Of Clinical Study Of Novel True Human Therapeutic Antibody For Treating Serious Infections Due To Staphylococcus Aureus     3/9/2016
Aridis Pharmaceuticals Expands Patent Portfolio For Several Fully Human Monoclonal Antibodies Against Infectious Disease Targets     2/24/2016
Allergan (AGN) Release: FDA Accepts Supplemental New Drug Application (sNDA) For TEFLARO (ceftaroline fosamil)     2/16/2016
Allergan (AGN) Announces FDA Approval Of Updated Label For New Dosing Regimen For DALVANCE (dalbavancin)     1/21/2016